"VGS Initiates U.S. Pivotal Trial To Evaluate The Use Of Its VEST Technology For Bypass Surgery"
Vascular Graft Solutions Ltd (VGS) announces on enrollment of the first 20 patients into the VEST U.S. pivotal trial that will evaluate the safety and effectiveness of the VEST, a novel external support device for treatment of saphenous vein graft disease after coronary artery bypass grafting. "Our goal in CTSN is to foster a culture of rigorous scientific comparison and to promote the evaluation of surgical procedures, devices, and related management strategies, directed at improving cardiovascular disease outcomes," said Annetine Gelijns, PhD, JD, principal investigator of the CTSN Data Coordinating Center and professor and system chair of population health science and policy at the Icahn School of Medicine at Mount Sinai. The study is conducted under the clinical leadership of John Puskas, MD, director of surgical coronary revascularization for the Mount Sinai Health System. “I am proud to serve as the joint PI for the VEST trial in the United States. This is one of the most exciting potential cardiovascular therapies to be rigorously testing in many years,” said Dr. Gelijns.
- Annetine C. Gelijns, PhD, JD, Professor, System Chair, Population Health Science and Policy, Icahn School of Medicine at Mount Sinai
- John D. Puskas, MD, Site Chair, Cardiovascular Surgery, Mount Sinai St. Luke’s, Mount Sinai West, Mount Sinai Beth Israel, Professor, Cardiovascular Surgery, Icahn School of Medicine at Mount Sinai, Director, Surgical Coronary Revascularization, Mount Sinai Health System
Additional coverage:
Markets Insider
KLTV News
Fox 21 News
Times Herald
KSLA News